Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000)
D E FURST, F C BREEDVELD, G R BURMESTER, J J CROFFORD, P EMERY, M FELDMANN, J R KALDEN, A F KAVANAUGH, E C KEYSTONE, L G KLARESKOG, P E LIPSKY, R N MAINI, A S RUSSELL, D L SCOTT, J S SMOLEN, L B A VAN DE PUTTE, T L VISHER, and M H WEISMAN
Ann Rheum Dis 2000; 59 (Supplement 1
): i1-i2. doi:10.1136/ard.59.suppl_1.i1
[Extract]
[Full text]
[PDF]
[Request Permissions]
Post-transcriptional regulation of tumour necrosis factor production
Paul Anderson
Ann Rheum Dis 2000; 59 (Supplement 1
): i3-i5. doi:10.1136/ard.59.suppl_1.i3
[Extract]
[Full text]
[PDF]
[Request Permissions]
Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF- B
Bharat B Aggarwal
Ann Rheum Dis 2000; 59 (Supplement 1
): i6-i16. doi:10.1136/ard.59.suppl_1.i6
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Targeting interleukin 18 with interleukin 18 binding protein
Charles A Dinarello
Ann Rheum Dis 2000; 59 (Supplement 1
): i17-i20. doi:10.1136/ard.59.suppl_1.i17
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
Norihiro Nishimoto, Tadamitsu Kishimoto, and Kazuyuki Yoshizaki
Ann Rheum Dis 2000; 59 (Supplement 1
): i21-i27. doi:10.1136/ard.59.suppl_1.i21
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Clinical outcome measures in rheumatoid arthritis
Piet L C M van Riel and Anke M van Gestel
Ann Rheum Dis 2000; 59 (Supplement 1
): i28-i31. doi:10.1136/ard.59.suppl_1.i28
[Extract]
[Full text]
[PDF]
[Request Permissions]
Efficacy and toxicity of old and new disease modifying antirheumatic drugs
Peter Tugwell, Vivian Welch, Maria Suarez-Almazor, Beverley Shea, and George Wells
Ann Rheum Dis 2000; 59 (Supplement 1
): i32-i35. doi:10.1136/ard.59.suppl_1.i32
[Extract]
[Full text]
[PDF]
[Request Permissions]
Which post-marketing database and studies does EMEA require
Gottfried Kreutz and Leng Heng
Ann Rheum Dis 2000; 59 (Supplement 1
): i36-i37. doi:10.1136/ard.59.suppl_1.i36
[Extract]
[Full text]
[PDF]
[Request Permissions]
The role of national agencies in the managed introduction of new drugs for arthritis
Katrina Simister
Ann Rheum Dis 2000; 59 (Supplement 1
): i38-i40. doi:10.1136/ard.59.suppl_1.i38
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update
Mark W Davis, Ulrich Feige, Alison M Bendele, Steven W Martin, and Carl K Edwards, III
Ann Rheum Dis 2000; 59 (Supplement 1
): i41-i43. doi:10.1136/ard.59.suppl_1.i41
[Extract]
[Full text]
[PDF]
[Request Permissions]
Update on D2E7: a fully human anti-tumour necrosis factor monoclonal antibody
Joachim Kempeni
Ann Rheum Dis 2000; 59 (Supplement 1
): i44-i45. doi:10.1136/ard.59.suppl_1.i44
[Extract]
[Full text]
[PDF]
[Request Permissions]
Etanercept (Enbrel): update on therapeutic use
George Spencer-Green
Ann Rheum Dis 2000; 59 (Supplement 1
): i46-i49. doi:10.1136/ard.59.suppl_1.i46
[Abstract]
[Full text]
[PDF]
[Request Permissions]
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function
Francis Ka-Ming Chan
Ann Rheum Dis 2000; 59 (Supplement 1
): i50-i53. doi:10.1136/ard.59.suppl_1.i50
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NF B in tumour necrosis factor production
Brian M J Foxwell, Jan Bondeson, Fionula Brennan, and Marc Feldmann
Ann Rheum Dis 2000; 59 (Supplement 1
): i54-i59. doi:10.1136/ard.59.suppl_1.i54
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Biological role of interleukin 1 receptor antagonist isoforms
William P Arend and Carla J Guthridge
Ann Rheum Dis 2000; 59 (Supplement 1
): i60-i64. doi:10.1136/ard.59.suppl_1.i60
[Abstract]
[Full text]
[PDF]
[Request Permissions]
The role of angiogenesis in rheumatoid arthritis: recent developments
Alisa Erika Koch
Ann Rheum Dis 2000; 59 (Supplement 1
): i65-i71. doi:10.1136/ard.59.suppl_1.i65
[Extract]
[Full text]
[PDF]
[Request Permissions]
The final pathogenetic steps in focal bone erosions in rheumatoid arthritis
Steven R Goldring
Ann Rheum Dis 2000; 59 (Supplement 1
): i72-i74. doi:10.1136/ard.59.suppl_1.i72
[Extract]
[Full text]
[PDF]
[Request Permissions]
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor
Richard O Williams, Marc Feldmann, and Ravinder N Maini
Ann Rheum Dis 2000; 59 (Supplement 1
): i75-i80. doi:10.1136/ard.59.suppl_1.i75
[Extract]
[Full text]
[PDF]
[Request Permissions]
Arguments for interleukin 1 as a target in chronic arthritis
Wim B van den Berg
Ann Rheum Dis 2000; 59 (Supplement 1
): i81-i84. doi:10.1136/ard.59.suppl_1.i81
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor : first clinical and laboratory experiences
Jürgen Braun, Jian Xiang, Jan Brandt, Hardy Maetzel, Hildrun Haibel, Peihua Wu, Siegfried Kohler, Martin Rudwaleit, Stefanie Siegert, Andreas Radbruch, Andreas Thiel, and Joachim Sieper
Ann Rheum Dis 2000; 59 (Supplement 1
): i85-i89. doi:10.1136/ard.59.suppl_1.i85
[Extract]
[Full text]
[PDF]
[Request Permissions]
Activation of cytokines as a mechanism of disease progression in heart failure
Biykem Bozkurt
Ann Rheum Dis 2000; 59 (Supplement 1
): i90-i93. doi:10.1136/ard.59.suppl_1.i90
[Extract]
[Full text]
[PDF]
[Request Permissions]
Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system
Krzysztof W Selmaj
Ann Rheum Dis 2000; 59 (Supplement 1
): i94-i102. doi:10.1136/ard.59.suppl_1.i94
[Extract]
[Full text]
[PDF]
[Request Permissions]
Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis
Michael H Schiff
Ann Rheum Dis 2000; 59 (Supplement 1
): i103-i108. doi:10.1136/ard.59.suppl_1.i103
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Advances in interleukin 2 receptor targeted treatment
John C Morris and Thomas A Waldmann
Ann Rheum Dis 2000; 59 (Supplement 1
): i109-i114. doi:10.1136/ard.59.suppl_1.i109
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Jaks and Stats as therapeutic targets
John J O'Shea, Roberta Visconti, Tammy P Cheng, and Massimo Gadina
Ann Rheum Dis 2000; 59 (Supplement 1
): i115-i118. doi:10.1136/ard.59.suppl_1.i115
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Future prospects for anti-cytokine treatment
Marc Feldmann, Jadwiga Miotla, Ewa Paleolog, Richard Williams, Anne-Marie Malfait, Peter Taylor, Fionula M Brennan, and Ravinder N Maini
Ann Rheum Dis 2000; 59 (Supplement 1
): i119-i122. doi:10.1136/ard.59.suppl_1.i119
[Abstract]
[Full text]
[PDF]
[Request Permissions]